Yuxia Liu

Yuxia Liu

Auto-generated profile, based on publicly available information

Yuxia Liu

Department of Chemistry, National University of Singapore, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2024 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
YLYuxia Liu
Yuxia Liu
YHYuanyuan He
Yuanyuan He
JTJiahuan Tong
Jiahuan Tong
SGShengyang Guo
Shengyang Guo
XZXinyu Zhang
Xinyu Zhang
XLXIAOGANG LIU
XIAOGANG LIU

13 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YLYuxia Liu
Yuxia Liu
DGDuyang Gao
Duyang Gao
YHYuanyuan He
Yuanyuan He
JMJing Ma
Jing Ma
SCSuet Yen Chong
Suet Yen Chong
XLXIAOGANG LIU
XIAOGANG LIU
Magnetic resonance imaging contrast agents can enhance diagnostic precision but often face limitations such as short imaging windows, low tissue specificity, suboptimal contrast enhancement, or potential toxicity, which affect resolution and long-term monitoring. Here, we present a protein contrast agent based on lanmodulin, engineered with a single-point mutation at position 108 from N to D to yield maximum gadolinium binding sites. After loading with Gd3+ ions, the resulting protein complex, LanND-Gd, exhibits efficient renal clearance, high relaxivity, and prolonged renal retention compared to commercial agents. LanND-Gd enables high-performance visualization of whole-body structures and brain vasculature in male mice at a resolution finer than one hundred micrometers. In male ischemia mouse models, LanND-Gd also improves kidney dysfunction monitoring while minimizing risks of neural toxicity or immunogenic reactions. This protein-based contrast agent offers superior image quality, improved biocompatibility, and extended imaging timeframes, promising significant advancements in magnetic resonance-based diagnostics and patient outcomes.

25 February 2026 in Accounts of Chemical Research
Verified
Journal Article
Closed access
YLYuxia Liu
Yuxia Liu
JCJiaye Chen
Jiaye Chen
XLXIAOGANG LIU
XIAOGANG LIU

1 July 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
YYYang Yan
Yang Yan
YWYiping Wang
Yiping Wang
YLYuxia Liu
Yuxia Liu
TCTao Chen
Tao Chen
YZYaoli Zhu
Yaoli Zhu
FKFangen Kong
Fangen Kong
Purpose: Long non-coding RNAs (lncRNAs) have been reported to be involved in a variety of cancers, including glioma. However, the exact role and underlying mechanism of lncRNA AGAP2 antisense RNA 1 (AGAP2-AS1) in glioma have not yet been fully elucidated. Methods: The expression levels of AGAP2-AS1, microRNA-628-5p (miR-628-5p) and pleiotrophin (PTN) were measured by quantitative real-time polymerase chain reaction (qRT-PCR). Cell proliferation, apoptosis, migration and invasion were detected by Cell Counting Kit-8 (CCK-8) assay, flow cytometry, transwell assay, respectively. Western blot assay was used to detect the protein level of PTN. The interaction between miR-628-5p and AGAP2-AS1 or PTN was predicted by bioinformatics software and confirmed by the dual-luciferase reporter and RNA Immunoprecipitation (RIP) assays. Murine xenograft model was established to confirm the role of AGAP2-AS1 in glioma progression in vivo. Results: AGAP2-AS1 expression was upregulated in glioma tissues and cells. Knockdown of AGAP2-AS1 inhibited the proliferation, migration and invasion, but facilitated apoptosis in glioma cells. Moreover, AGAP2-AS1 could directly bind to miR-628-5p and its overexpression reversed the anti-tumor effect of miR-628-5p restoration on the progression of glioma cells. In addition, miR-628-5p directly targeted PTN and its inhibition abolished the inhibitory effect of PTN knockdown on the progression of glioma cells. Furthermore, AGAP2-AS1 functioned as a competing endogenous RNA (ceRNA) by sponging miR-628-5p to modulate PTN expression. Besides, AGAP2-AS1 depletion reduced tumor growth by upregulating miR-628-5p and downregulating PTN. Conclusion: AGAP2-AS1 knockdown suppressed cell proliferation, migration and invasion but promoted cell apoptosis in glioma cells by regulating miR-628-5p/PTN axis, providing novel avenues for treatment of glioma.

30 July 2026 in Frontiers in Science
Verified
Journal Article
Open access
PDF file
YLYuxia Liu
Yuxia Liu
ZCZixuan Chen
Zixuan Chen
MSMingyu Sui
Mingyu Sui
HWHongxuan Wang
Hongxuan Wang
MBMarco Bettinelli
Marco Bettinelli
XLXIAOGANG LIU
XIAOGANG LIU
Lanthanide-based carriers have emerged as powerful platforms for next-generation biomedical imaging, combining unique optical and magnetic features to address key limitations of conventional agents. Owing to their 4f electron configuration, lanthanide ions provide sharp emission lines, long lifetimes, high photostability, and strong paramagnetism, enabling high-resolution, multiplexed, and deep-tissue imaging with minimal photodamage. This review surveys recent advances across optical, X-ray, and magnetic resonance modalities, focusing on how material design influences performance. We examine representative carriers, such as lanthanide-doped nanoparticles, organic complexes, and lanthanide-binding proteins, and their roles in near-infrared (NIR) imaging (long-term single-particle tracking, molecular sensing, and NIR-II modalities), X-ray imaging (contrast media, scintillators, and persistent emitters for low-dose diagnostics), and magnetic resonance imaging (chemical and biosynthetic agents with enhanced relaxivity, specificity, and safety, including targeted protein constructs). We highlight molecular engineering and surface modification strategies that boost signal and biocompatibility, and discuss emerging directions such as artificial intelligence-enabled data analysis and the integration of multimodal probes to deliver integrated anatomical and functional information. While most advances are still at the proof-of-concept stage, lanthanide carriers show great potential for bridging materials science, biophysics, and clinical needs, and are reshaping biomedical imaging toward more precise, responsive, and personalized diagnostics.

3 April 2026 in Nature Sensors
Verified
Journal Article
Closed access
PDF file
MSMingyu Sui
Mingyu Sui
JLJingzhun Liu
Jingzhun Liu
CFChaoyu Fu
Chaoyu Fu
YLYuxia Liu
Yuxia Liu
JYJie Yan
Jie Yan
XLXIAOGANG LIU
XIAOGANG LIU